Neuronetics, Inc.

Neuronetics, Inc. is a commercial-stage medical technology company dedicated to designing, developing, and marketing products that enhance the quality of life for patients suffering from psychiatric disorders. Incorporated in Delaware and headquartered in Malvern, PA, the company's mission is to renew lives by transforming neurohealth, emphasizing that mental health is as crucial as physical health.

The company's primary product is the NeuroStar Advanced Therapy System, a non-invasive, non-systemic, office-based treatment utilizing transcranial magnetic stimulation (TMS). This FDA-cleared therapy is used for major depressive disorder (MDD) in adults who have not achieved satisfactory improvement from prior antidepressant medication. It is also indicated as an adjunct for obsessive-compulsive disorder (OCD) and MDD in adolescents aged 15-21. Neuronetics markets its NeuroStar system to psychiatrists, mental health clinics, and hospitals across the United States and in select international markets, including Japan.

Neuronetics holds a leading market position in the non-invasive brain stimulation sector for MDD. In December 2024, the company acquired Greenbrook TMS Inc., integrating clinic operations to expand patient access and drive growth. This acquisition is projected to contribute to double-digit revenue growth for 2025 and achieve cash flow breakeven in the third quarter of 2025. Leadership saw a transition with Keith J. Sullivan announcing his retirement as CEO effective June 30, 2026, and Dan Reuvers appointed as the new President and CEO as of March 23, 2026.